{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:00:49Z","timestamp":1766088049406,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104297"],"award-info":[{"award-number":["82104297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008301"],"award-info":[{"award-number":["2020YFC2008301"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cbi.2023.110531","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T21:08:04Z","timestamp":1683320884000},"page":"110531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS\/MS"],"prefix":"10.1016","volume":"380","author":[{"given":"Qingqing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaojie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saili","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5046-9806","authenticated-orcid":false,"given":"Ruanjuan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2023.110531_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2023.110531_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.toxlet.2020.11.016","article-title":"Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment","volume":"337","author":"Quignot","year":"2021","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.cbi.2023.110531_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Pharmacogenetics implementation, clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2023.110531_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis","volume":"78","author":"Milosavljevic","year":"2021","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.cbi.2023.110531_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"year":"2022","series-title":"Mavacamten, a First-In-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy","author":"Dalo","key":"10.1016\/j.cbi.2023.110531_bib6"},{"key":"10.1016\/j.cbi.2023.110531_bib7","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2023.110531_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2023.110531_bib9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.cbi.2023.110531_bib10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cbi.2023.110531_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003495-200060040-00006","volume":"60","author":"Figgitt","year":"2000","journal-title":"Fluvoxamine, Drugs"},{"key":"10.1016\/j.cbi.2023.110531_bib12","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cbi.2023.110531_bib13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJM199411173312008","volume":"331","author":"Gram","year":"1994","journal-title":"Fluoxetine, New England J. Med."},{"key":"10.1016\/j.cbi.2023.110531_bib14","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1128\/AAC.00423-11","article-title":"Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use","volume":"55","author":"Damle","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2023.110531_bib15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:14:29Z","timestamp":1757859269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279723001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":15,"alternative-id":["S0009279723001989"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110531","relation":{},"ISSN":["0009-2797"],"issn-type":[{"type":"print","value":"0009-2797"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110531"}}